Literature DB >> 28095928

One hundred years of external approach medialisation thyroplasty.

V E Crolley1, N Gibbins1.   

Abstract

It has been 100 years since Erwin Payr first developed an operation to improve the effects of a paralysed vocal fold, and operations based on this technique are still in use today. This technique, medialisation thyroplasty, aims to improve the symptoms caused by vocal fold palsy by realigning the lateralised vocal fold into the midline. Whilst the effects of vocal fold palsy were recognised in antiquity, it was only with the development of indirect laryngoscopy in the late nineteenth century that the vocal fold paralysis could be identified as an aetiology for poor phonation and dysphagia. Payr, in 1915, was the first to perform a recognisable form of medialisation thyroplasty, which was further developed in the early twentieth century, but medialisation thyroplasty did not begin to be widely used until the development of the modern technique by Isshiki et al., in 1974. Since then, medialisation thyroplasty has continued to be developed and is currently the most widely used technique for correcting the effects of vocal fold palsy. However, a wide array of therapeutic options is now available for vocal fold palsy and it is impossible to say whether or not medialisation thyroplasty will still be used in another 100 years.

Entities:  

Keywords:  Deglutition Disorders; History; Inventions; Laryngoplasty; Laryngoscopy; Larynx; Otolaryngology; Phonation; Thyroid Cartilage; Vocal Cord Paralysis; Vocal Cords

Mesh:

Year:  2017        PMID: 28095928     DOI: 10.1017/S0022215116010033

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  1 in total

1.  Thyroplasty in unilateral vocal fold paresis with coexisting hereditary hemorrhagic telenagiectasia: A case report.

Authors:  Joanna Jackowska; Hanna Klimza; Natalia Zagozda; Marc Remacle; Waldemar Wojnowski; Krzysztof Piersiala; Małgorzata Wierzbicka
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.